Aro Biotherapeutics Targets CD40 Pathway in Myositis

Preclinical findings on its ABX1200 RNA treatment for inflammatory myositis were presented at ACR Convergence 2026.

Updated on Nov. 19, 2026 in Biotech

Bold vector editorial illustration of a clear glass vessel of amber fluid with a teal thread suspended inside and coral cords fanning behind, evoking a biotech therapy targeting inflammatory muscle disease.
Aro Biotherapeutics presented preclinical data at ACR Convergence 2026 linking elevated CD40 activity in inflamed muscle to disease, and plans to test its RNA therapy ABX1200 in people in 2027. AI Illustration. Upload story photo >

Aro Biotherapeutics, working with Sweden's Karolinska Institute, presented preclinical data on ABX1200, an RNA-based treatment for inflammatory myositis, at ACR Convergence 2026 in Orlando. The company plans to begin clinical testing of the therapy in 2027.

Why it matters

The findings link elevated CD40 expression in inflamed muscle to disease activity, providing a biological rationale for suppressing CD40 as a treatment strategy. Advancing the program into human testing would be the next step in evaluating whether this approach is viable.

The results come from preclinical laboratory experiments and an animal model of muscle inflammation rather than human trials. Whether the reduction in CD40 signaling seen in these models translates to patients remains unknown until clinical studies begin in 2027.

The players

Aro Biotherapeutics

A Philadelphia-based biotechnology company developing RNA-based therapies, including ABX1200, using its proprietary Centyrin delivery technology.

Karolinska Institute

A Swedish medical university and research institution in Stockholm that collaborated with Aro Biotherapeutics on the CD40 research.

The details

Researchers found CD40 expression elevated in muscle samples from patients with inclusion body myositis, with CD40L present in certain circulating T cells and in immune cells infiltrating affected tissue. ABX1200 uses small interfering RNA to reduce CD40 production by targeting its messenger RNA, combined with Centyrin delivery technology intended to direct the therapy toward skeletal muscle and inflammatory immune cells.

Timeline

  1. ACR Convergence 2026 in Orlando, Florida, where the preclinical findings were presented last week.

  2. 2027: planned start of clinical testing of ABX1200.

Pipeline Context

The work builds on the established role of the CD40/CD40L pathway in immune-mediated disease, extending that research toward an RNA-based approach in inflammatory myositis. Advancing from preclinical models to the 2027 clinical start would place the program within the broader effort to test CD40-directed therapies in muscle disease.

Any eventual therapy would need to show benefit in patients before reaching clinics, so the findings do not yet change treatment options for people with inflammatory myositis. The planned 2027 trials would be the first point at which patients could potentially be enrolled.

The takeaway

Preclinical results identify a potential target, but human trial data will determine whether suppressing CD40 helps patients with inflammatory myositis. Readers should watch for clinical study announcements from Aro Biotherapeutics beginning in 2027.

What happens next

Aro Biotherapeutics plans to initiate clinical testing of ABX1200 in 2027, which would move the program into human studies.

Further reading

Explore more Biotech coverage for context on drug development pipelines like this one.

Source note: This article includes information reported by MyChesCo.